Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by ...

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment ...

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day ...

Ruth Beadle, head, global supply chain, Sanofi, discusses how digital integration, advanced planning, and sustainability goals are transforming end-to-end supply chain operations to improve scale, ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

The Low-Income Subsidy, or "Extra Help," significantly reduces prescription drug costs for 14 million Medicare beneficiaries with limited income and resources. The Inflation Reduction Act eliminated ...

Ruth Beadle, head, global supply chain, Sanofi, discusses the company’s multi-year effort to build an AI-powered, end-to-end supply chain focused on improving service, resilience, and cost efficiency.

In the third part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, dives into the barriers limiting AI and automation’s widespread adoption in R&D ...